Skip to main content

Table 2 Effect of cisplatin (CP) and different treatments of AHE on liver biomarkers in serum

From: Modulatory influence of Acacia hydaspica R. Parker ethyl acetate extract against cisplatin inveigled hepatic injury and dyslipidemia in rats

Group ALT (U/l) AST (U/l) ALP (U/l) LDH (U/l)
Control 44.63 ± 0.49 b 72.83 ± 0.12b 120.7 ± 0.33 b 70.50 ± 1.04b
CP 138.3 ± 0.29a 192.4 ± 0.35a 350.0 ± 0.58 a 92.83 ± 0.60a
AHE alone 44.57 ± 0.23b 72.63 ± 0.19 b 120.9 ± 0.21b 70.33 ± 0.67b
CP + AHE 101.8 ± 0.28a, b, d 140.4 ± 0.30 a, b, d 299.2 ± 0.42a, b, d 84.67 ± 0.67a, b, d
AHE + CP 46.60 ± 0.31a, b, c 75.97 ± 0.55a, b, c 135.8 ± 0.28a, b, c 76.30 ± 0.35a, b, c
CP + Sily 47.17 ± 0.17a**, b 75.53 ± 0.53 a, b 134.0 ± 0.55a, b 73.50 ± 0.50b
  1. Values expressed as mean ± SEM
  2. a Significance at p < 0.0001 Vs. control group
  3. b Significance at p < 0.0001 Vs. Cisplatin (CP) group
  4. c Significance at p < 0.0001 of AHE + CP pre-treated group Vs. CP + AHE post-treated group
  5. d Significance at p < 0.0001 of CP + AHE treatment groups Vs CP + Sily group
  6. ** Significant difference at p < 0.001. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters (One way ANOVA followed by Tukey’s multiple comparison tests)